Effect of omalizumab on patients with chronic urticaria: Issues with the determination of autoimmune urticaria [3]

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 1, 2008, Pages 88-

  Sheikh, Javed ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB;

ANTIGEN EXPRESSION; ASSAY; AUTOIMMUNITY; BASOPHIL; CHRONIC URTICARIA; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; LETTER; PRIORITY JOURNAL; REFERENCE VALUE; URTICARIA;

EID: 37849010586     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60412-7     Document Type: Letter

References (5)

1. Spector SL, Tan RA. Effect of omalizumab on patients with chronic Urticaria. Ann Allergy Asthma Immunol. 2007;99:190-193.
2. Yasnowsky KM, Dreskin SC, Efaw B, et al. Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol. 2006;117:1430-1434.
3. Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005;5:403-407.
4. Sabroe RA, Francis DM, Barr RM, Black AK, Greaves MW. Anti-Fc(ε)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol. 1998;102:651-658.
5. Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FεRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119:441-448.